Prior Auth Required

31868 - trial. Lancet. 2017;390( ):849-860. doi:10.1016/ -6736(17) -8

This procedure appears on the selected insurer prior authorization source.

Check another codeExplore policy data
Prior authorizationPrior Auth Required
Procedure / Servicetrial. Lancet. 2017;390( ):849-860. doi:10.1016/ -6736(17) -8
Procedure / Service Description

Updated Accessed - 2 Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in 7/2017 1/2026 patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390(10097):849-860. doi:10.1016/S0140-6736(17)31868-8 CAPITAL DISTRICT PHYSICIANS’ HEALTH PLAN, INC. CAPITAL DISTRICT PHYSICIANS’ HEALTHCARE NETWORK, INC.

Likely documents
  • Confirm benefit details
  • Submit clinical notes if requested by the plan
Next actions
  • Confirm the current plan policy before submission.
  • Use the insurer authorization workflow for this listed code.